Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation

Leuk Lymphoma. 2021 Jan;62(1):86-94. doi: 10.1080/10428194.2020.1821006. Epub 2020 Sep 16.

Abstract

Monomorphic post-transplant lymphoproliferative disorder (M-PTLD) occurring after solid organ transplant histologically resembles aggressive non-Hodgkin lymphomas, with diffuse large B-cell lymphoma being the most common. In a cohort of 40 patients with DLBCL-type M-PTLD, inferior progression free survival (PFS) was observed for Revised International Prognostic Index (R-IPI) >2 (p = 0.01) and high-risk pathologic features (p = 0.02), defined by double expressor lymphoma, MYC rearrangement, or increased copy number of either MYC or BCL2. Overall survival (OS) was inferior in R-IPI >2 (p = 0.002) and high-risk pathologic features (p = 0.003). Combining both R-IPI >2 and high-risk pathologic features resulted in well-delineated good, intermediate, and poor risk groups of DLBCL-type M-PTLD with respect to both PFS and OS (p < 0.001). Our results demonstrate a prognostic role for both the R-IPI score and presence of high-risk pathologic features in DLBCL-type M-PTLD.

Keywords: PTLD; Post-transplant lymphoproliferative disorder; monomorphic; outcome; survival.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Disease Progression
  • Epstein-Barr Virus Infections*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / etiology
  • Lymphoproliferative Disorders* / diagnosis
  • Lymphoproliferative Disorders* / etiology
  • Organ Transplantation* / adverse effects
  • Progression-Free Survival